MX2011008060A - Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. - Google Patents
Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.Info
- Publication number
- MX2011008060A MX2011008060A MX2011008060A MX2011008060A MX2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- treatment
- disorders
- compounds
- brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20664209P | 2009-02-02 | 2009-02-02 | |
| PCT/US2010/000255 WO2010087981A2 (en) | 2009-02-02 | 2010-01-29 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008060A true MX2011008060A (es) | 2011-09-09 |
Family
ID=42396261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008060A MX2011008060A (es) | 2009-02-02 | 2010-01-29 | Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2391621A4 (https=) |
| JP (1) | JP2012516845A (https=) |
| KR (1) | KR20110115139A (https=) |
| CN (1) | CN102369201A (https=) |
| AU (1) | AU2010208646A1 (https=) |
| BR (1) | BRPI1005316A2 (https=) |
| CA (1) | CA2751285A1 (https=) |
| EA (1) | EA018994B1 (https=) |
| IL (1) | IL214392A0 (https=) |
| MX (1) | MX2011008060A (https=) |
| SG (1) | SG173168A1 (https=) |
| WO (2) | WO2010087981A2 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1367056A1 (en) * | 1992-07-24 | 2003-12-03 | The Regents Of The University Of California | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US20020099050A1 (en) * | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| DK1026950T3 (da) * | 1997-10-27 | 2006-06-26 | Univ California | Behandling af skizofreni med ampakiner og neuroleptika |
| WO2008143963A1 (en) * | 2007-05-17 | 2008-11-27 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| US8263591B2 (en) * | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
-
2010
- 2010-01-29 BR BRPI1005316-6A patent/BRPI1005316A2/pt not_active IP Right Cessation
- 2010-01-29 SG SG2011054376A patent/SG173168A1/en unknown
- 2010-01-29 KR KR1020117019461A patent/KR20110115139A/ko not_active Withdrawn
- 2010-01-29 JP JP2011547981A patent/JP2012516845A/ja active Pending
- 2010-01-29 CN CN2010800154033A patent/CN102369201A/zh active Pending
- 2010-01-29 WO PCT/US2010/000255 patent/WO2010087981A2/en not_active Ceased
- 2010-01-29 EP EP10736150A patent/EP2391621A4/en not_active Withdrawn
- 2010-01-29 WO PCT/US2010/000254 patent/WO2010087980A2/en not_active Ceased
- 2010-01-29 EA EA201101162A patent/EA018994B1/ru not_active IP Right Cessation
- 2010-01-29 MX MX2011008060A patent/MX2011008060A/es active IP Right Grant
- 2010-01-29 CA CA2751285A patent/CA2751285A1/en not_active Abandoned
- 2010-01-29 AU AU2010208646A patent/AU2010208646A1/en not_active Abandoned
-
2011
- 2011-08-01 IL IL214392A patent/IL214392A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010087980A2 (en) | 2010-08-05 |
| EA018994B1 (ru) | 2013-12-30 |
| EP2391621A4 (en) | 2012-07-25 |
| WO2010087981A3 (en) | 2011-03-24 |
| SG173168A1 (en) | 2011-08-29 |
| AU2010208646A1 (en) | 2011-09-01 |
| BRPI1005316A2 (pt) | 2019-09-24 |
| EP2391621A2 (en) | 2011-12-07 |
| IL214392A0 (en) | 2011-09-27 |
| WO2010087980A3 (en) | 2011-02-24 |
| JP2012516845A (ja) | 2012-07-26 |
| EA201101162A1 (ru) | 2012-01-30 |
| KR20110115139A (ko) | 2011-10-20 |
| CN102369201A (zh) | 2012-03-07 |
| WO2010087981A2 (en) | 2010-08-05 |
| CA2751285A1 (en) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200901546A1 (ru) | Дизамещенные амиды для усиления глутаматергических синаптических ответов | |
| CO6362014A2 (es) | Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso | |
| ECSP18043573A (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño | |
| SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| PA8750901A1 (es) | Bifenilsulfonilos y fenil heteroaril sulfonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor | |
| GT200500336A (es) | Derivados de 3-fenil-pirazol como moduladores del receptor 5ht 2a de la serotonina utiles para el tratamiento de trastornos relacionados con este | |
| EA201000516A1 (ru) | 3-замещенные 1,2,3-триазин-4-оны и 3-замещенные 1,3-пиримидин-оны для усиления глутаматергических синаптических ответов | |
| CR20130339A (es) | Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos | |
| DOP2012000167A (es) | Moduladores alostericos positivos de receptores m1 de la quinolina amida | |
| GT201300324A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| MX336549B (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| BRPI1013377A2 (pt) | formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| NI200900131A (es) | Compuesto de [1,2,3]-benzotriazinona-3-. sustituid | |
| CL2012003212A1 (es) | Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson. | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| GT201000170A (es) | Derivados de ciclopropilamina | |
| CY1122017T1 (el) | Υποκατεστημενες ενωσεις χρωμανης ως ρυθμιστες του υποδοχεα ανιχνευτη ασβεστιου | |
| CL2012002570A1 (es) | Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios. | |
| CO6491034A2 (es) | Derivados de amida espirocíclicos | |
| CR20120247A (es) | Canfenos arilados novedosos, procesos para su preparación y usos | |
| JOP20220102A1 (ar) | مثبطات المُسْتقبلة الأدرينِية adrac2 | |
| SV2009002917A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| CL2008000289A1 (es) | Compuestos derivados de pirano[2,3-b]piridina, moduladores del receptor cannabinoide-1; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como psicosis, enfermedad de alzheimer, migrana, enfermedad de parkinson, asma y obesida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |